Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells

Immunology

Volumn 144, Issue 1, 2015, Pages 21-33

  Portillo, Jose Andres C ^a   Greene, Jennifer A ^a   Schwartz, Isaac ^a   Subauste, Maria Cecilia ^a,b   Subauste, Carlos S ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Endothelial cell; Epithelial cell; Inflammation; Monocyte; Muscle smooth cell

Indexed keywords

CCL2 PROTEIN, HUMAN; CD40 ANTIGEN; CD40 LIGAND; ICAM1 PROTEIN, HUMAN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; PEROXIDASE; THROMBOPLASTIN; TRAF3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DENDRITIC CELL; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; MESANGIUM CELL; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD40; CD40 LIGAND; CELL LINE; CHEMOKINE CCL2; DENDRITIC CELLS; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MESANGIAL CELLS; MICE; MYOCYTES, SMOOTH MUSCLE; PEPTIDES; PEROXIDASES; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 3; TNF RECEPTOR-ASSOCIATED FACTOR 6; UP-REGULATION;

EID: 84918784241     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12361     Document Type: Article

References (71)

1. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-35.
2. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67:2-17.
3. Karmann K, Hughes CCW, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995; 92:4342-6.
4. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94:1931-6.
5. Xu H, Zhang X, Mannon RB, Kirk AD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest 2006; 116:769-74.
6. Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009; 21:293-300.
7. Yellin MJ, D'Agati V, Parkinson G et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritis. Arthritis Rheum 1997; 40:124-34.
8. Battaglia E, Biancone L, Resegotti A, Emanuelli G, Ruggero Fronda G, Camussi G. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am J Gastroenterol 1999; 94:3279-84.
9. Hakkinen T, Karkola K, Yla-Herttualla S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Virchows Arch 2000; 437:396-405.
10. Bruemmer D, Riggers U, Holzmeister J et al. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions. Am J Cardiol 2001; 87:21-7.
11. Ohashi Y, Okazaki H, Sato T, Miura S, Amada N, Yamaguchi M. Function of CD40/CD40L in peritubular capillary renal allograft rejection. Transplant Proc 2001; 33:407-8.
12. Borcherding F, Nitschke M, von Smolinski D, Bieber K, van Kooten C, Lehnert H, Fellermann K, Buning J. The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am J Pathol 2010; 176:1816-27.
13. Song Z, Jin R, Yu S, Nanda A, Granger DL, Li G. Crucial role of CD40 signaling in vascular wall cells in neointima formation and vascular remodeling after vascular interventions. Atheroscler Thromb Vasc Biol 2012; 32:50-64.
14. Gaweco AS, Mitchell BL, Lucas BA, McClatchey KD, van Thiel DH. CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in human chronic renal allograft rejection. Kidney Int 1999; 55:1543-52.
15. Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA, Fiocchi C. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003; 124:1249-64.
16. Davis B, Zou M-H. CD40 ligand-dependent tyrosine nitration of prostacyclin synthase in vivo. Circulation 2005; 112:2184-92.
17. Kornbluth RS, Kee K, Richman DD. CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive β-chemokines. Proc Natl Acad Sci USA 1998; 95:5205-10.
18. Mukundan L, Milhorn DM, Matta B, Suttles J. CD40-mediated activation of vascular smooth muscle cell chemokine production through a Src-initiated. MAPK-dependent pathway. Cell Signal 2004; 16:375-84.
19. Mukundan L, Bishop GA, Head KZ, Zhang L, Wahl L, Suttles J. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. J Immunol 2005; 174:1081-90.
20. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40. Induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96:396-9.
21. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T-lymphocytes. A role for CD40 signaling in plaque rupture? Circ Res 1997; 81:448-54.
22. Schonbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR, Libby P. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000; 156:7-14.
23. Deckers JGM, de Haij S, van der Woude FJ, van der Kooij SW, Daha MR, van Kooten C. IL-4 and IL-13 augment cytokine- and CD40-induced RANTES production by human renal tubular epithelial cells in vitro. J Am Soc Nephrol 1998; 9:1187-93.
24. Li H, Nord EP. CD40 ligation stimulates MCP-1 and IL-8 production, TRAF6 recruitment, and MAPK activation in proximal tubule cells. Am J Physiol Renal Physiol 2002; 282:F1020-33.
25. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154:1470-80.
26. Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin-12 secretion. J Exp Med 1996; 183:693-8.
27. Kirk AD, Harlan DM, Armstrong NM et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94:8789-94.
28. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 1998; 394:200-3.
29. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 2000; 97:7458-63.
30. Lutgens E, Cleutjens KBJM, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJAP. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 2000; 97:7464-89.
31. + T cells by blocking the CD40-CD154 interactions. J Immunol 2000; 164:6005-14.
32. Boumpas DT, Furie R, Manzi S, Ilei GG, Wallace DJ, Balow JE, Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48:719-27.
33. Ruth A-J, Kitching AR, Semple TJ, Tipping PG, Holdsworth SR. Intrinsic renal cell expression of CD40 directs Th1 effectors inducing experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003; 14:2813-22.
34. Vowinkel T, Anthoni C, Wood KC et al. CD40-CD40 ligand mediates the recruitment of leukocytes and platelets in the inflamed murine colon. Gastroenterology 2007; 132:955-65.
35. Donners MMPC, Beckers L, Lievens D et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood 2008; 111:4596-604.
36. Lutgens E, Lievens D, Beckers L et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207:391-404.
37. Bishop GA, Hostager BS, Brown KD. Mechanisms of TNF receptor-associated factor (TRAF) regulation in B lymphocytes. J Leukoc Biol 2002; 72:19-23.
38. Hanissian SH, Geha R. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997; 6:379-88.
39. Pullen SS, Miller HG, Everdeen DS, Dang TT, Crute JJ, Kehry MR. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 1998; 37:11836-45.
40. Lu LF, Cook WJ, Lin LL, Noelle RJ. CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J Biol Chem 2003; 278:45414-18.
41. Baccam M, Bishop GA. Membrane-bound CD154, but not anti-CD40 mAb, induces NF-κB independent B cell IL-6 production. Eur J Immunol 1999; 29:3855-66.
42. Ahonen CL, Manning EM, Erickson LD, O'Connor BP, Lind EF, Pullen SS, Kehry MR, Noelle RJ. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol 2002; 3:451-6.
43. Mackey MF, Wang Z, Eichelberg K, Germain RN. Distinct contributions of different CD40 TRAF binding sites to CD154-induced dendritic cell maturation and IL-12 secretion. Eur J Immunol 2003; 33:779-89.
44. Andrade RM, Wessendarp M, Gubbels MJ, Striepen B, Subauste CS. CD40 induces macrophage anti-Toxoplasma gondii activity by triggering autophagy-dependent fusion of pathogen-containing vacuoles and lysosomes. J Clin Invest 2006; 116:2366-77.
45. Subauste CS, Andrade RM, Wessendarp M. CD40-TRAF6 and autophagy-dependent anti-microbial activity in macrophages. Autophagy 2007; 3:245-8.
46. Portillo J-AC, Muniz-Feliciano L, Subauste MC, Heinzel FP, Subauste CS. CD40 and TNF-α synergize to induce nitric oxide synthase in macrophages. Immunology 2012; 135:140-50.
47. Jabara HH, Laouini D, Tsitsikov E et al. The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching. Immunity 2002; 17:265-76.
48. Davies CC, Mak TW, Young LS, Eliopoulos AG. TRAF6 is required for TRAF2-dependent CD40 signal transduction in non-hemopoietic cells. Mol Cel Biol 2005; 25:9806-19.
49. Pukerson JM, Smith RS, Pollock SJ, Phipps RP. The TRAF6, but not the TRAF2/3, binding domain of CD40 is required for cytokine production in human lung fibroblasts. Eur J Immunol 2005; 35:2920-8.
50. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-κB and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 2001; 166:6812-19.
51. Zirlik A, Bavendiek U, Libby P et al. TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Atheroscler Thromb Vasc Biol 2007; 27:1101-7.
52. Ogolla P, Portillo J-AC, White CL, Patel K, Lamb B, Sen GC, Subauste CS. The protein kinase double-stranded RNA-dependent (PKR) enhances protection against disease cause by a non-viral pathogen. PLoS Pathog 2013; 9:e100557.
53. Subauste CS, Wessendarp M. Human dendritic cells discriminate between viable and killed Toxoplasma gondii tachyzoites: dendritic cell activation after infection with viable parasites results in CD28 and CD40 ligand signaling that controls IL-12-dependent and -independent T cell production of IFN-γ. J Immunol 2000; 165:1498-505.
54. Haswell LE, Glennie MJ, Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 2001; 31:3094-100.
55. Portillo J-AC, Van Grol J, Zheng L et al. CD40 mediates retinal inflammation and neuro-vascular degeneration. J Immunol 2008; 181:8719-26.
56. Hsing Y, Hostager BS, Bishop GA. Characterization of CD40 signaling determinants regulating nuclear factor-κB activation in B lymphocytes. J Immunol 1997; 159:4898-906.
57. Jalukar SV, Hostager BS, Bishop GA. Characterization of the roles of TNF receptor-associated factor 6 in CD40-mediated B lymphocyte effector functions. J Immunol 2000; 164:623-30.
58. Andrade RM, Wessendarp M, Portillo J-AC, Yang J-Q, Gomez FJ, Durbin JE, Bishop GA, Subauste CS. TRAF6 signaling downstream of CD40 primes macrophages to acquire anti-microbial activity in response to TNF-α. J Immunol 2005; 175:6014-21.
59. Haxhinasto SA, Hostager BS, Bishop GA. Cutting Edge: molecular mechanisms of synergy between CD40 and the B cell antigen receptor: role for TNF receptor-associated factor 2 in receptor interaction. J Immunol 2002; 169:1145-9.
60. Nishikawa K, Guo YJ, Miyasaka M, Tamatani T, Collins AB, Sy MS, McCluskey RT, Andres G. Antibodies to intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis. J Exp Med 1993; 177:667-77.
61. Okada S, Shikata K, Matsuda M et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003; 52:2586-93.
62. Baran D, Vendeville B, Ogborn M, Katz N. Cell adhesion molecule expression in murine lupus-like nephritis induced by lipopolysaccharide. Nephron 2000; 84:167-76.
63. Dal Canton A, Fuiano G, Sepe V, Caglioti A, Ferrone S. Mesangial expression of intercellular adhesion molecule-1 in primary glomerulosclerosis. Kidney Int 1992; 41:951-5.
64. Prive GG, Melnick A. Specific peptides for the therapeutic targeting of oncogenes. Curr Opin Gen Dev 2006; 16:71-7.
65. Taniguchi T, Tsukada H, Nakamura H, Kodama M, Fukuda K, Saito T, Miyasaka M, Seino Y. Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats. J Gastroenterol Hepatol 1998; 13:945-9.
66. Huo Y, Hafezi-Moghadam A, Ley K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ Res 2000; 87:153-9.
67. Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, Beaudet AL. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Atheroscler Thromb Vasc Biol 1997; 17:1517-20.
68. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2:275-81.
69. Egashira K, Zhao Q, Kataoka C et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002; 90:1167-72.
70. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascular Pharmacol 2012; 56:232-44.
71. Johnson RM, Harrison SD, Maclean D. Therapeutic applications of cell-penetrating peptides. Methods Mol Biol 2011; 683:535-51.